Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 501-507, December 2009

New agents for AML and MDS

  • Steven Grant, MD (Professor)

      Affiliations

    • Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, VCU Health Systems, 401 College Street, Richmond, VA 23298-0035, USA
    • Department of Biochemistry, Virginia Commonwealth University and Massey Cancer Center, VCU Health Systems, 401 College Street, Richmond, VA 23298-0035,USA
    • Department of Pharmacology, Virginia Commonwealth University and Massey Cancer Center, VCU Health Systems, 401 College Street, Richmond, VA 23298-0035, USA
    • Corresponding Author InformationTel.: +1 804 828 5211; Fax: +1 804 828 2174.

The heterogeneity of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has led to a multiplicity of treatments, from cytotoxic agents to signal transduction modulators, cell-cycle inhibitors and epigenetic therapies. While some have shown promising initial results, the outlook for AML patients, particularly older and relapsed patients, as well as patients whose cells exhibit certain adverse chromosomal abnormalities or mutant oncoproteins, continues to be grim. Combination chemotherapy using new agents that act at a number of different levels may provide the greatest potential for successful future therapies. A select number of new agents, approaches and combinations are reviewed here.

Keywords: acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), FMS-like tyrosine kinase receptors (FLT3 inhibitors), farnesyl transferase inhibitor (FTI), clofarabine, histone deacetylase (HDAC), DNMT, mTOR, parthenolide, PIM kinase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(09)00061-9

doi:10.1016/j.beha.2009.08.003

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 501-507, December 2009

Article Tools